慢性丙型病毒性肝炎（CHC）是由丙型肝炎病毒（HCV）慢性感染引发的病毒性肝炎。HCV在全球人群中普遍易感且广泛流行，急性感染者可能会进展为慢性肝炎，即CHC。传统治疗方案采用干扰素联合利巴韦林，整体治愈率低且伴随严重的不良反应，包括发烧、脱发、抑郁 ...

For a decade now, the world has had highly effective medications for hepatitis C infections. In the United States, they’ve mostly been sitting on the shelf, according to a new study. These drugs, ...

Background. Few direct anti–hepatitis C virus (HCV) agents have been studied in difficult-to-treat null responder and cirrhotic human immunodeficiency virus (HIV)-coinfected patients. Daclatasvir and ...

Atea Pharmaceuticals announced a successful End-of-Phase 2 meeting with the FDA and plans to start patient enrollment for its global Phase 3 program for treating hepatitis C virus (HCV) in April 2025.

Atea Pharmaceuticals announced the ongoing enrollment in its Phase 3 C-BEYOND trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV). Positive ...

The majority of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) coinfection occurs among persons who inject drugs. Rapid improvements in responses to HCV therapy have been observed, but ...

There’s a highly effective and often curative treatment for people with hepatitis C, but less than a third of insured patients get it within a year of diagnosis, according to a new study. The ...

Combination therapy with peginterferon alfa and ribavirin now eliminates detectable hepatitis C virus (HCV) from the blood of more than half of patients with long-term infections. However, many of ...

The experts agree. Improved results, shorter treatment durations, and, thus, superior tolerability, make sofosbuvir (Sovaldi) and simeprevir (Olysio) breakthrough agents in the fight against the ...

GENT, Belgium--(BUSINESS WIRE)--Fujirebio Europe today announced the availability* of the INNO-LiPA HCV 2.0 Genotyping assay. The product, previously distributed by Siemens Healthcare Diagnostics Inc.